Legal & General Group Plc Takes $9.79 Million Position in Lantheus Holdings, Inc. $LNTH

Legal & General Group Plc bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to its most recent filing with the SEC. The firm bought 88,207 shares of the medical equipment provider’s stock, valued at approximately $9,786,000. Legal & General Group Plc owned approximately 0.14% of Lantheus as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of LNTH. Farallon Capital Management LLC raised its stake in shares of Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after purchasing an additional 1,950,252 shares during the last quarter. Norges Bank purchased a new stake in Lantheus in the fourth quarter valued at approximately $76,197,000. Freestone Grove Partners LP increased its holdings in Lantheus by 4,114.8% in the 4th quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock worth $40,497,000 after buying an additional 594,088 shares during the period. Assenagon Asset Management S.A. increased its holdings in Lantheus by 440.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after buying an additional 582,661 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its position in Lantheus by 686.1% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock worth $45,423,000 after buying an additional 522,678 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $100.96 on Tuesday. The company has a market capitalization of $6.59 billion, a PE ratio of 24.39 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The company’s fifty day moving average price is $103.64 and its 200 day moving average price is $92.00. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The firm had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. During the same quarter in the previous year, the business earned $1.57 EPS. Lantheus’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, research analysts predict that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on LNTH shares. Citizens Jmp restated a “market outperform” rating and set a $115.00 price objective on shares of Lantheus in a research note on Monday, June 29th. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Truist Financial downgraded Lantheus from a “buy” rating to a “hold” rating and cut their price target for the stock from $125.00 to $102.50 in a research report on Monday, August 3rd. Brookline Capital Markets lowered Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Leerink Partners set a $102.50 price objective on Lantheus in a report on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $108.11.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.